Beam’s Base-Edited Sickle Cell Therapy Meets Pivotal Trial Goal
Beam Therapeutics said on Tuesday that its experimental gene-edited therapy for sickle cell disease met the main goal of its pivotal trial, moving the company closer to seeking United States approval for what could be the first base-editing medicine ever submitted to regulators.
Beam announced the results on Tuesday, 10 November, from the BEACON Phase 1/2 study of ristoglogene autogetemcel, known as risto-cel. The company said the trial achieved its primary efficacy endpoint and met all of its primary safety endpoints at a prespecified interim analysis.
The announcement is a milestone for a technology that edits single letters of DNA rather than cutting the double helix. If the US Food and Drug Administration accepts and approves the application Beam plans to file, risto-cel would become the first base-edited therapy to reach American patients.
What the BEACON trial showed
The BEACON trial tested risto-cel in people with sickle cell disease who suffer severe vaso-occlusive crises, painful episodes in which sickled red blood cells block blood flow. The primary endpoint was freedom from severe crises for at least 12 consecutive months, judged by independent adjudicators.
As of the data cutoff on 20 October, 49 people had received the one-time treatment: 39 adults and 10 adolescents. Of those, 31 had completed the follow-up period required for the primary endpoint.
Beam said the study also met all of its secondary endpoints, including freedom from inpatient hospitalisation for severe crises for at least 12 consecutive months. The trial is open-label and single-arm, meaning every participant received the therapy and there was no placebo group for comparison.
The numbers Beam did not share
The announcement left an important question unanswered. Beam did not disclose what proportion of the 31 patients with enough follow-up actually achieved 12 months without a severe crisis, nor did it publish detailed safety data.
BioPharma Dive reported that the result represents the first positive late-stage readout for base editing, while analysts at H.C. Wainwright noted that the company had not disclosed the response rate or safety details.
Beam said detailed results will be presented at a medical meeting in 2027, with data from an earlier cutoff at the American Society of Hematology meeting in New Orleans in December.
What base editing is, and why it matters
Risto-cel, formerly known as BEAM-101, is made from a patient’s own blood stem cells. The cells are collected, edited outside the body, and then returned to the patient after conditioning chemotherapy clears space in the bone marrow.
The editing targets the genes that control foetal haemoglobin, a form of the oxygen-carrying protein that sickle cell patients normally stop producing after infancy. By switching foetal haemoglobin back on, the therapy aims to stop red blood cells from sickling.
About 100,000 Americans live with sickle cell disease, according to the US Centers for Disease Control and Prevention, and the condition disproportionately affects Black Americans. Severe crises can cause organ damage, strokes and shortened lives. It is the latest advance from American research teams working to turn gene editing into routine medicine.
The road to the FDA
Beam said it expects to submit a biologics licence application to the FDA as early as the end of 2026. The filing would be the company’s first, and the first ever for a base-edited therapy.
The path has not been smooth. In November 2024, Beam disclosed that a patient in the BEACON trial had died of respiratory failure four months after receiving treatment. The company said at the time that the death was not considered related to risto-cel itself, but the episode underlined the risks that surround the intensive chemotherapy patients must undergo before any gene-edited cell therapy.
For patients and their families, the more important date is the filing itself. If the application is accepted, the FDA will review the full data set — including the numbers Beam has not yet released — before deciding whether risto-cel can be offered as a treatment. Until then, the result is a promising signal, not yet a medicine.
Frequently asked questions
What is risto-cel?
Risto-cel is a one-time cell therapy made from a patient’s own blood stem cells, edited using base editing to reactivate foetal haemoglobin and prevent red blood cells from sickling.
What did the BEACON trial show?
The trial met its primary endpoint of at least 12 consecutive months without a severe vaso-occlusive crisis, as judged by independent adjudicators, and met all primary safety endpoints at an interim analysis.
When could risto-cel reach patients?
Beam plans to submit an approval application to the FDA as early as the end of 2026. Approval, if granted, would follow a regulatory review of the full data.
